LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today reported financial results for the third quarter ended September 30, 2007. “This was a significant quarter for EPIX – one that was marked by clinical successes, pipeline progress and corporate growth,” said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. “We are excited by the results of our Phase 1b clinical trial of PRX-07034 in obesity and our Phase 2a clinical trial of PRX-08066 in patients with pulmonary hypertension (PH) associated with COPD. We’ve also achieved key milestones under our strategic collaborations with GlaxoSmithKline and Cystic Fibrosis Foundation Therapeutics, and have completed enrollment into both our Phase 2b trial of PRX-00023 in major depressive disorder and our Phase 2a trial of PRX-03140 in Alzheimer’s disease. We are continuing to advance our programs on-schedule and deliver on key corporate goals.”
